Recursion CSO heads west for mini-brain upstart; Novartis vet steps up to the plate as CFO for Andrew Hirsch at C4 Therapeutics

Sharath Hegde

A few months ago, as Recursion hammered out an IPO that would value them at over $3 billion, its CSO, Sharath Hegde, hopped on a plane and flew to San Francisco to visit a small, modestly backed startup, working out of an unmarked...

Click to view original post